Vous avez cherché: macitentan (Croate - Anglais)

djelatna tvar je macitentan.
the active substance is macitentan.

opsumit 10 mg tablete macitentan
opsumit 10 mg tablets macitentan

macitentan i njegov aktivni metabolit
macitentan and its active metabolite

opsumit 10 mg filmom obložene tablete macitentan
opsumit 10 mg film-coated tablets macitentan

macitentan ima četiri primarna puta metaboličke razgradnje.
macitentan has four primary metabolic pathways.

usporedba terapija: macitentan 10 mg naspram placeba
treatment comparison: macitentan 10 mg vs placebo

macitentan nije supstrat za p-gp/mdr-1.
macitentan is not a substrate for p- gp/mdr-1.

macitentan je davan zdravim ispitanicima kao pojedinačna doza do 600 mg.
macitentan has been administered as a single dose of up to 600 mg to healthy subjects.

macitentan malo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
macitentan may have a minor influence on the ability to drive and use machines.

macitentan se pokazao teratogen u kunića i štakora pri svim ispitanim dozama.
macitentan was teratogenic in rabbits and rats at all doses tested.

macitentan 10 mg poboljšao je kvalitetu života prema procjeni upitnikom sf-36.
macitentan 10 mg improved quality of life assessed by the sf-36 questionnaire.

djelatna tvar lijeka opsumit, macitentan, djeluje blokirajući „receptore endotelina”.
the active substance in opsumit, macitentan, works by blocking ‘endothelin receptors’.

macitentan nije bio fototoksičan in vivo nakon pojedinačne doze pri izloženosti do 24 puta većoj od izloženosti u ljudi.
macitentan was not phototoxic in vivo after single dose at exposures of up to 24-fold the human exposure.

macitentan i njegov aktivni metabolit nemaju klinički značajne inhibitorne ili induktivne učinke na enzime citokroma p450.
macitentan and its active metabolite do not have clinically relevant inhibitory or inducing effects on cytochrome p450 enzymes.

macitentan i njegov aktivni metabolit nisu relevantni supstrati oatp1b1 i oatp1b3, ali ulaze u jetru pasivnom difuzijom.
macitentan and its active metabolite are not relevant substrates of oatp1b1 and oatp1b3, but enter the liver by passive diffusion.

opsumit sadrži djelatnu tvar macitentan koja pripada skupini lijekova zvanih “antagonisti receptora endotelina“.
opsumit contains the active substance macitentan, which belongs to the class of medicines called “endothelin receptor antagonists”.

macitentan je inducirao minimalnu do blagu hiperplaziju sluznice i upalnu infiltraciju podsluznice nosne šupljine u ispitivanjima kancerogenosti na miševima u svim dozama.
macitentan induced minimal to slight mucosal hyperplasia and inflammatory infiltration in the submucosa of the nasal cavity in the mouse carcinogenicity study at all doses.

u zdravih ispitanika, izloženost macitentanu i njegovom aktivnom metabolitu nije izmijenjena u prisutnosti hrane i stoga se macitentan može uzimati s hranom ili bez nje.
in healthy subjects, the exposure to macitentan and its active metabolite is unchanged in the presence of food and, therefore, macitentan may be taken with or without food.

macitentan je peroralno aktivan, potentan antagonist endotelinskih receptora aktivan na eta i na etb receptorima i približno 100 puta selektivniji za eta u usporedbi s etb in vitro.
macitentan is an orally active potent endothelin receptor antagonist, active on both eta and etb receptors and approximately 100-fold more selective for eta as compared to etb in vitro.

macitentan inhibira protein rezistencije karcinoma dojke (bcrp; breast cancer resistance protein) pri klinički relevantnim koncentracijama u crijevima.
macitentan inhibits the breast cancer resistance protein (bcrp) at clinically relevant intestinal concentrations.